Mecamylamine: Difference between revisions
No edit summary |
No edit summary |
||
Line 26: | Line 26: | ||
|adverseReactions= | |adverseReactions= | ||
[[orthostatic hypotension]] and [[syncope]] | |||
<!--Black Box Warning--> | <!--Black Box Warning--> |
Revision as of 01:16, 5 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Mecamylamine is a autonomic ganglionic blocker that is FDA approved for the {{{indicationType}}} of moderately severe to severe essential hypertension and uncomplicated cases of malignant hypertension. Common adverse reactions include orthostatic hypotension and syncope.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition1
- Dosing Information
- Dosage
Condition2
- Dosing Information
- Dosage
Condition3
- Dosing Information
- Dosage
Condition4
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Mecamylamine in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Mecamylamine in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Mecamylamine in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Mecamylamine in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Mecamylamine in pediatric patients.
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Mecamylamine in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Mecamylamine in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Mecamylamine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Mecamylamine during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Mecamylamine with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Mecamylamine with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Mecamylamine with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Mecamylamine with respect to specific gender populations.
Race
There is no FDA guidance on the use of Mecamylamine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Mecamylamine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Mecamylamine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Mecamylamine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Mecamylamine in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Mecamylamine in the drug label.
Condition1
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Mecamylamine in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Mecamylamine in the drug label.
Pharmacology
Mecamylamine
| |
Systematic (IUPAC) name | |
(1S,2R,4R)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine | |
Identifiers | |
CAS number | |
ATC code | C02 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
Mol. mass | 167.291 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 40% |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status |
Template:Unicode Prescription only |
Routes | Oral |
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Mecamylamine in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Mecamylamine in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Mecamylamine in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Mecamylamine in the drug label.
Condition1
- Description
How Supplied
Storage
There is limited information regarding Mecamylamine Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Mecamylamine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Mecamylamine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Mecamylamine in the drug label.
Precautions with Alcohol
- Alcohol-Mecamylamine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- ®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Empty citation (help)
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Mecamylamine |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage= |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Mecamylamine |Label Name=Mecamylamine02.png
}}
{{#subobject:
|Label Page=Mecamylamine |Label Name=Mecamylamine02.png
}}